Symbols / ZVSA
ZVSA Chart
About
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.94M |
| Enterprise Value | 1.42M | Income | -25.70M | Sales | — |
| Book/sh | -1.45 | Cash/sh | 0.07 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -0.05 | PEG | — |
| P/S | — | P/B | -0.17 | P/C | — |
| EV/EBITDA | -0.19 | EV/Sales | — | Quick Ratio | 0.04 |
| Current Ratio | 0.08 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.32 | EPS next Y | -4.80 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 | ROA | -46.30% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 8.10M |
| Shs Float | 7.68M | Short Float | 7.38% | Short Ratio | 0.25 |
| Short Interest | — | 52W High | 1.94 | 52W Low | 0.11 |
| Beta | 0.81 | Avg Volume | 75.68K | Volume | 1.74K |
| Target Price | — | Recom | None | Prev Close | $0.23 |
| Price | $0.24 | Change | 4.35% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.24
Latest analyst target
3. DCF / Fair value
$-8.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.24
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-03-12 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-02-29 | reit | HC Wainwright & Co. | Buy → Buy | $24 |
- Biotech ZyVersa Raises $2M in Strategic Warrant Deal to Advance Drug Development Pipeline - Stock Titan ue, 08 Jul 2025 07
- Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday? - Yahoo Finance hu, 10 Apr 2025 07
- ZyVersa Therapeutics to be delisted from Nasdaq, trading to move to OTC market - Investing.com Wed, 16 Jul 2025 07
- ZyVersa Therapeutics Enters Share Purchase Agreement with Williamsburg Venture Holdings to Advance Clinical Development of VAR 200 - Nasdaq Wed, 25 Jun 2025 07
- Patterns Watch: Is now the right time to enter WLDS - July 2025 PostEarnings & Growth Focused Stock Reports - baoquankhu1.vn ue, 24 Feb 2026 17
- Major Breakthrough: Simplified Approval Path for Rare Kidney Disease Drug Worth Billions - Stock Titan ue, 08 Apr 2025 07
- ZyVersa Therapeutics Updates Shareholders on Key Developments and R&D Milestones in Mid-Year Letter - Nasdaq Mon, 21 Jul 2025 07
- ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis - MarketBeat hu, 22 Dec 2022 10
- Is Katapult Holdings Inc. on track to beat earnings - July 2025 Chart Watch & Fast Gaining Stock Reports - mfd.ru Sat, 14 Feb 2026 17
- Why Is Aclarion (ACON) Stock Down 19% Today? - InvestorPlace Mon, 26 Feb 2024 08
- ZVSA - ZyVersa Therapeutics Inc Latest Stock News & Market Updates - Stock Titan ue, 03 Jan 2023 15
- ETF Watch: Can Smart Powerr Corp beat the S P 500 - Weekly Stock Report & Precise Trade Entry Recommendations - baoquankhu1.vn hu, 29 Jan 2026 23
- Decoding ZyVersa Therapeutics’ Recent Swings: Should Investors Take Note? - timothysykes.com ue, 05 Nov 2024 08
- Why Is Intuitive Machines (LUNR) Stock Down 23% Today? - InvestorPlace Mon, 26 Feb 2024 08
- Why Is Cidara Therapeutics (CDTX) Stock Down 12% Today? - InvestorPlace hu, 23 Mar 2023 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -8.19M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.09 | 0.00 | 0.00 |
| NormalizedEBITDA | -9.13M | 78.92M | -13.00M | -7.69M |
| TotalUnusualItems | 0.00 | -93.33M | -607.00K | 441.58K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -93.33M | -607.00K | 441.58K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -9.41M | -98.30M | -14.05M | -8.08M |
| ReconciledDepreciation | 6.93K | 10.40K | 9.87K | 10.40K |
| EBITDA | -9.13M | -14.41M | -13.61M | -7.25M |
| EBIT | -9.14M | -14.42M | -13.62M | -7.26M |
| NetInterestIncome | -269.86K | 457.00 | -427.54K | -821.37K |
| InterestExpense | 427.54K | 821.37K | ||
| InterestIncome | 457.00 | |||
| NormalizedIncome | -9.41M | -13.15M | -13.44M | -8.53M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -9.41M | -98.30M | -14.05M | -8.08M |
| TotalExpenses | 9.14M | 14.42M | 13.01M | 7.70M |
| TotalOperatingIncomeAsReported | -9.14M | -107.75M | -13.01M | -7.70M |
| DilutedAverageShares | 1.11M | 97.50K | 69.13K | 57.79K |
| BasicAverageShares | 1.11M | 97.50K | 69.13K | 57.79K |
| DilutedEPS | -8.48 | -1.09K | -346.50 | -139.88 |
| BasicEPS | -8.48 | -1.09K | -346.50 | -139.88 |
| DilutedNIAvailtoComStockholders | -9.41M | -106.25M | -24.06M | -8.08M |
| NetIncomeCommonStockholders | -9.41M | -106.25M | -24.06M | -8.08M |
| PreferredStockDividends | 7.95M | 10.02M | ||
| NetIncome | -9.41M | -98.30M | -14.05M | -8.08M |
| NetIncomeIncludingNoncontrollingInterests | -9.41M | -98.30M | -14.05M | -8.08M |
| NetIncomeContinuousOperations | -9.41M | -98.30M | -14.05M | -8.08M |
| TaxProvision | 6.75K | -9.46M | 0.00 | 0.00 |
| PretaxIncome | -9.41M | -107.75M | -14.05M | -8.08M |
| OtherIncomeExpense | -93.33M | -607.00K | 441.58K | |
| SpecialIncomeCharges | 0.00 | -93.33M | 0.00 | 213.48K |
| OtherSpecialCharges | -213.48K | |||
| WriteOff | 0.00 | 81.44M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 11.90M | 0.00 | |
| GainOnSaleOfSecurity | -607.00K | 228.10K | ||
| NetNonOperatingInterestIncomeExpense | -269.86K | 457.00 | -427.54K | -821.37K |
| TotalOtherFinanceCost | 269.86K | -457.00 | ||
| InterestExpenseNonOperating | 427.54K | 821.37K | ||
| InterestIncomeNonOperating | 457.00 | |||
| OperatingIncome | -9.14M | -14.42M | -13.01M | -7.70M |
| OperatingExpense | 9.14M | 14.42M | 13.01M | 7.70M |
| ResearchAndDevelopment | 1.78M | 3.21M | 5.41M | 2.12M |
| SellingGeneralAndAdministration | 7.36M | 11.21M | 7.61M | 5.58M |
| GeneralAndAdministrativeExpense | 7.36M | 11.21M | 7.61M | 5.58M |
| OtherGandA | 7.36M | 11.21M | 7.61M | 5.58M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 7.00 | 6.00 | ||
| OrdinarySharesNumber | 2.51M | 405.20K | 25.95K | 25.95K |
| ShareIssued | 2.51M | 405.21K | 25.95K | 25.95K |
| NetDebt | 8.82M | |||
| TotalDebt | 0.00 | 8.66K | 108.76K | 9.15M |
| TangibleBookValue | -10.13M | -7.57M | -11.99M | -12.50M |
| InvestedCapital | 8.52M | 11.07M | 99.99M | -3.35M |
| WorkingCapital | -9.52M | -6.84M | -1.83M | -12.81M |
| NetTangibleAssets | -10.13M | -7.57M | -11.99M | -12.50M |
| CapitalLeaseObligations | 0.00 | 8.66K | 108.76K | 0.00 |
| CommonStockEquity | 8.52M | 11.07M | 99.99M | -12.50M |
| PreferredStockEquity | 1.00 | 1.00 | 2.00 | |
| TotalCapitalization | 8.52M | 11.07M | 99.99M | -12.50M |
| TotalEquityGrossMinorityInterest | 8.52M | 11.07M | 99.99M | -12.50M |
| StockholdersEquity | 8.52M | 11.07M | 99.99M | -12.50M |
| OtherEquityInterest | 331.33K | 331.33K | ||
| TreasuryStock | 7.17K | 7.17K | 0.00 | |
| RetainedEarnings | -112.63M | -103.22M | -4.92M | -52.90M |
| AdditionalPaidInCapital | 121.16M | 114.30M | 104.58M | 40.07M |
| CapitalStock | 252.00 | 41.00 | 28.00 | 242.00 |
| CommonStock | 251.00 | 40.00 | 26.00 | 242.00 |
| PreferredStock | 1.00 | 1.00 | 2.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 12.08M | 11.04M | 18.51M | 13.63M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 851.66K | 844.91K | 10.32M | 0.00 |
| NonCurrentDeferredLiabilities | 851.66K | 844.91K | 10.32M | 0.00 |
| NonCurrentDeferredTaxesLiabilities | 851.66K | 844.91K | 10.32M | 0.00 |
| CurrentLiabilities | 11.23M | 10.19M | 8.19M | 13.63M |
| OtherCurrentLiabilities | 7.26K | 507.26K | 1.15M | 1.71M |
| CurrentDeferredLiabilities | 0.00 | 16.91K | ||
| CurrentDebtAndCapitalLeaseObligation | 8.66K | 108.76K | 9.15M | |
| CurrentCapitalLeaseObligation | 0.00 | 8.66K | 108.76K | 0.00 |
| CurrentDebt | 9.15M | |||
| OtherCurrentBorrowings | 9.15M | |||
| PayablesAndAccruedExpenses | 11.22M | 9.68M | 6.93M | 2.75M |
| CurrentAccruedExpenses | 1.89M | 1.25M | 798.46K | 748.77K |
| InterestPayable | 0.00 | 748.77K | ||
| Payables | 9.34M | 8.43M | 6.13M | 2.00M |
| TotalTaxPayable | 0.00 | 106.68K | 0.00 | |
| IncomeTaxPayable | 0.00 | 106.68K | 0.00 | |
| AccountsPayable | 9.34M | 8.43M | 6.03M | 2.00M |
| TotalAssets | 20.60M | 22.11M | 118.51M | 1.13M |
| TotalNonCurrentAssets | 18.88M | 18.76M | 112.14M | 314.39K |
| NonCurrentPrepaidAssets | 178.48K | 98.48K | 46.66K | 286.66K |
| NonCurrentDeferredAssets | 57.24K | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 18.65M | 18.65M | 111.98M | 0.00 |
| OtherIntangibleAssets | 18.65M | 18.65M | 100.09M | |
| Goodwill | 0.00 | 11.90M | 0.00 | |
| NetPPE | 0.00 | 14.77K | 115.70K | 27.73K |
| AccumulatedDepreciation | -52.00K | -45.07K | -34.67K | -24.27K |
| GrossPPE | 52.00K | 59.84K | 150.37K | 52.00K |
| OtherProperties | 52.00K | 59.84K | 150.37K | 52.00K |
| CurrentAssets | 1.72M | 3.35M | 6.36M | 811.78K |
| OtherCurrentAssets | 184.87K | 215.46K | 225.35K | 106.93K |
| PrepaidAssets | 0.00 | 235.00K | 376.27K | |
| CashCashEquivalentsAndShortTermInvestments | 1.53M | 3.14M | 5.90M | 328.58K |
| CashAndCashEquivalents | 1.53M | 3.14M | 5.90M | 328.58K |
| CashFinancial | 1.53M | 3.14M | 5.90M | 328.58K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.56M | -8.72M | -1.49M | -5.08M |
| RepurchaseOfCapitalStock | 0.00 | -10.70M | 0.00 | |
| IssuanceOfDebt | 0.00 | 5.23M | ||
| IssuanceOfCapitalStock | 0.00 | 18.11M | 1.96M | 0.00 |
| EndCashPosition | 1.53M | 3.14M | 699.32K | 328.58K |
| BeginningCashPosition | 3.14M | 5.90M | 328.58K | 174.67K |
| ChangesInCash | -1.61M | -2.76M | 370.74K | 153.91K |
| FinancingCashFlow | 5.95M | 5.96M | 1.87M | 5.23M |
| CashFlowFromContinuingFinancingActivities | 5.95M | 5.96M | 1.87M | 5.23M |
| NetOtherFinancingCharges | -588.04K | -2.42M | -99.14K | |
| ProceedsFromStockOptionExercised | 6.54M | 967.48K | 0.00 | 0.00 |
| NetPreferredStockIssuance | 0.00 | -10.70M | 1.96M | 0.00 |
| PreferredStockPayments | 0.00 | -10.70M | 0.00 | |
| PreferredStockIssuance | 0.00 | 1.96M | 0.00 | |
| NetCommonStockIssuance | 0.00 | 18.11M | 0.00 | 0.00 |
| CommonStockPayments | 0.00 | -7.17K | 0.00 | |
| CommonStockIssuance | 0.00 | 18.11M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 5.23M | ||
| NetShortTermDebtIssuance | 0.00 | 5.23M | ||
| ShortTermDebtIssuance | 0.00 | 5.23M | ||
| NetLongTermDebtIssuance | 5.23M | |||
| LongTermDebtIssuance | 5.23M | |||
| OperatingCashFlow | -7.56M | -8.72M | -1.49M | -5.08M |
| CashFlowFromContinuingOperatingActivities | -7.56M | -8.72M | -1.49M | -5.08M |
| ChangeInWorkingCapital | 929.88K | 2.60M | 8.29M | -1.02M |
| ChangeInOtherWorkingCapital | 97.88K | |||
| ChangeInOtherCurrentLiabilities | -8.66K | -100.10K | -86.10K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 890.08K | 2.51M | 8.05M | -723.22K |
| ChangeInAccruedExpense | 139.51K | 101.53K | 1.43M | -411.36K |
| ChangeInPayable | 750.57K | 2.41M | 6.62M | -311.86K |
| ChangeInAccountPayable | 750.57K | 2.41M | 6.62M | -311.86K |
| ChangeInPrepaidAssets | -49.41K | 193.07K | 329.30K | -297.10K |
| OtherNonCashItems | 204.61K | 1.92M | 119.41K | 317.83K |
| StockBasedCompensation | 705.57K | 1.19M | 3.52M | 4.14M |
| AssetImpairmentCharge | 0.00 | 93.33M | 0.00 | |
| DeferredTax | 6.75K | -9.48M | 0.00 | 0.00 |
| DeferredIncomeTax | 6.75K | -9.48M | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 6.93K | 10.40K | 9.87K | 10.40K |
| DepreciationAndAmortization | 6.93K | 10.40K | 9.87K | 10.40K |
| Depreciation | 6.93K | 10.40K | 9.87K | 10.40K |
| OperatingGainsLosses | 607.00K | -441.58K | ||
| GainLossOnInvestmentSecurities | 607.00K | -228.10K | ||
| GainLossOnSaleOfPPE | -213.48K | |||
| NetIncomeFromContinuingOperations | -9.41M | -98.30M | -14.05M | -8.08M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ZVSA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|